200 related articles for article (PubMed ID: 32978223)
1. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
[TBL] [Abstract][Full Text] [Related]
4. Revefenacin: First Global Approval.
Heo YA
Drugs; 2019 Jan; 79(1):85-91. PubMed ID: 30560478
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease.
Lo A; Borin MT; Bourdet DL
Clin Pharmacokinet; 2021 Mar; 60(3):391-401. PubMed ID: 33124005
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Excretion, and Mass Balance of [
Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
[TBL] [Abstract][Full Text] [Related]
7. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Li F; Yang J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
[TBL] [Abstract][Full Text] [Related]
9. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
11. Revefenacin (Yupelri) for COPD.
Med Lett Drugs Ther; 2019 Jan; 61(1564):14-15. PubMed ID: 30856160
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
13. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
[TBL] [Abstract][Full Text] [Related]
14. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Disposition, and Biotransformation of [
Trivedi A; Wahlstrom J; Mackowski M; Dutta S; Lee E
Drug Metab Dispos; 2021 Aug; 49(8):619-628. PubMed ID: 34011533
[TBL] [Abstract][Full Text] [Related]
17. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
18. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B; Zan S; Luo W
Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
[TBL] [Abstract][Full Text] [Related]
20. Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects.
Vernillet L; Greene SA; Kim HW; Melnick SM; Glenn K
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):513-522. PubMed ID: 32301064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
